Pax Therapeutics Inc
PAX Therapeutics is a preclinical-stage gene delivery company based in Providence, RI, dedicated to advancing gene therapy for tendon and ligament injuries. Their proprietary gene therapy, PAX-001, utilizes a cutting-edge vector technology to stimulate the production of Type 1 collagen, resulting in faster and stronger healing of tendons, improved joint mobility, and decreased pain in humans and horses.
With a focus on localized delivery, PAX-001 can be easily administered through injection during repair surgery in humans and non-surgical ultrasound-guided injection in horses. Currently completing IND-enabling studies, PAX Therapeutics is on track to initiate clinical trials in the first half of 2025, aiming to provide both safety and efficacy data for their innovative gene therapy.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.
